Table 1 Baseline characteristics according to docetaxel regimens
Characteristic | 3-weekly docetaxel (n = 24) | 2-weekly docetaxel (n = 24) | P value |
|---|---|---|---|
Median age (years) (range) | 69.5 (52.3–83.9) | 64.6 (56.6–80.0) | 0.110 |
Site of metastasis | |||
Bone | 24 (100%) | 24 (100%) | 1.000 |
Liver | 2 (8.3%) | 1 (4.2%) | 0.500 |
Lung | 1 (4.2%) | 2 (8.3%) | 0.500 |
Lymph node | 10 (41.7%) | 18 (75%) | 0.019 |
Bladder | 1 (4.2%) | 3 (12.5%) | 0.609 |
Gleason score | 0.190 | ||
≤ 7 | 5 (20.8%) | 3 (12.5%) | |
8 | 6 (25.0%) | 5 (20.8%) | |
≥ 9 | 7 (29.2%) | 16 (66.7%) | |
Unknown | 6 (25.0%) | 0 (0%) | |
Median PSA (ng/mL) | |||
Baseline | 34.7 | 31.2 | 0.279 |
Nadir | 15.1 | 11.6 | 0.279 |
Previous therapy | |||
Prostatectomy | 4 (16.7%) | 4 (16.7%) | 0.500 |
Prostate radiotherapy | 2 (8.3%) | 1 (4.2%) | 0.500 |
Total dose (mg/m2), median | 395 | 320 | 0.011 |
Total # cycles, median (range) | 6 (1–11) | 8 (2–23) | 0.023 |
Mean dose (mg/m2) at each cycle, median | 68 (58–75) | 40 (35–40) | <0.001 |
Initial dose (mg/m2), median | 75 (60–75) | 40 (35–40) | <0.001 |